<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-65 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-65</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-65</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-7eeb4a455b84f804d702b1206a636084ccfea712</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/7eeb4a455b84f804d702b1206a636084ccfea712" target="_blank">Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> The coprimary overall survival (OS) end point of CheckMate 037 is reported, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma.</p>
                <p><strong>Cost:</strong> 0.011</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e65.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e65.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 037 - NIVO</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 037: Nivolumab versus Investigator's Choice Chemotherapy in ipilimumab‑refractory advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized, open‑label phase III trial comparing nivolumab (3 mg/kg IV every 2 weeks) versus investigator's choice chemotherapy in patients with unresectable stage IIIC/IV melanoma who progressed after anti‑CTLA‑4 (and BRAF inhibitor if BRAF V600 mutated); primary endpoints included objective response rate and overall survival with follow‑up ~2 years.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 037</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>advanced/metastatic (unresectable stage IIIC or IV; ipilimumab-refractory; BRAF-mutant patients had progressed after BRAF inhibitor)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Nivolumab 3 mg/kg IV every 2 weeks; patients treated until disease progression or unacceptable toxicity; investigators allowed continuation beyond progression if patient derived clinical benefit and tolerated therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td>4.7 months (95% CI, 3.3 to 6.0) for nivolumab; 2.0 months (95% CI, 1.6 to 2.8) for investigator's choice chemotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Complete response (CR), Partial response (PR), Stable disease (SD), Progressive disease (PD), Unable to determine (per RECIST v1.1)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td>No formal response‑adapted stopping rule reported; protocol specified treatment until progression or unacceptable toxicity, with allowance for continuing nivolumab beyond progression per investigator judgment if clinical benefit and tolerance.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Overall: median OS 15.7 months (95% CI, 12.9–19.9) for nivolumab vs 14.4 months (95% CI, 11.7–18.2) for chemotherapy (HR 0.95; 95.54% CI, 0.73–1.24). Median PFS 3.1 months (95% CI, 2.3–3.5) for nivolumab vs 3.7 months (95% CI, 2.3–5.3) for chemotherapy (HR ≈1.03; 95.1% CI, 0.78–1.436). ORR was 27% (74/272; 95% CI 22–33) with nivolumab vs 10% (13/133; 95% CI 5–16) with chemotherapy. Median duration of response was 31.9 months (95% CI, 25.9–31.9) for nivolumab vs 12.8 months (95% CI, 3.0–NR) for chemotherapy; 69% of nivolumab responses were ongoing at data cutoff vs 62% for chemotherapy. Sensitivity analysis censoring ICC patients at start of subsequent PD‑1/PD‑L1 therapy (treated population) yielded median OS 16.4 months for nivolumab vs 11.8 months for ICC (HR 0.81; 95% CI, 0.59–1.11), illustrating that post‑study PD‑1 exposure in the ICC arm influenced OS comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>Response breakdown (IRRC): Nivolumab — CR 17 (6%), PR 57 (21%), SD 55 (20%), PD 113 (42%), Unable to determine 30 (11%); ICC — CR 1 (1%), PR 12 (9%), SD 37 (28%), PD 36 (27%), Unable to determine 47 (35%). Median time to objective response: 2.2 months (nivolumab) vs 2.1 months (ICC). Median duration of response (overall responders): 31.9 months nivolumab vs 12.8 months ICC. No stratified OS/PFS reported by individual response categories (CR vs PR vs SD) in this manuscript.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td>Of randomized patients, a higher proportion assigned to ICC did not receive assigned therapy (23% ICC vs ~2% nivolumab). Median duration of therapy: 4.7 months (nivolumab) vs 2.0 months (ICC). Treatment‑related AEs led to discontinuation in 13 (5%) nivolumab‑treated patients vs 11 (11%) ICC patients; overall grade 3–4 treatment‑related AEs were 14% (nivolumab) vs 34% (ICC). Immune‑related AEs in the nivolumab group required systemic corticosteroids in 36% of patients. Most on‑study deaths were due to disease progression.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.", 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial <em>(Rating: 2)</em></li>
                <li>Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial <em>(Rating: 2)</em></li>
                <li>Pembrolizumab versus ipilimumab in advanced melanoma <em>(Rating: 2)</em></li>
                <li>Combined nivolumab and ipilimumab or monotherapy in untreated melanoma <em>(Rating: 2)</em></li>
                <li>Final overall survival for KEYNOTE-002: Pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>